Note 5 - Acquisition of EGEN, Inc. (Details) (USD $)	12 Months Ended				0 Months Ended	6 Months Ended	0 Months Ended	1 Months Ended	0 Months Ended
	Dec. 31, 2014		Dec. 31, 2013	Dec. 31, 2012	Aug. 02, 2016	Dec. 31, 2014	Jun. 10, 2014	Jun. 20, 2014	Dec. 31, 2014	Jun. 09, 2014
Note 5 - Acquisition of EGEN, Inc. (Details) [Line Items]
Business Combination, Consideration Transferred, Liabilities Incurred	$ 13,878,204
Business Combination, Acquisition Related Costs	1,385,263
Operating Expenses	25,215,194		15,911,485	22,142,717
Ovarian Cancer Study Milestone [Member] | EGEN, Inc. [Member]
Note 5 - Acquisition of EGEN, Inc. (Details) [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	12,000,000					12,000,000			12,000,000
Glioblastoma Multiforme Brain Cancer Study Milestone [Member] | EGEN, Inc. [Member]
Note 5 - Acquisition of EGEN, Inc. (Details) [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	12,000,000					12,000,000			12,000,000
TheraSilence Technology Milestone [Member] | EGEN, Inc. [Member]
Note 5 - Acquisition of EGEN, Inc. (Details) [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	6,000,000					6,000,000			6,000,000
Scenario, Forecast [Member] | EGEN, Inc. [Member]
Note 5 - Acquisition of EGEN, Inc. (Details) [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in Shares)					670,070
In Process Research and Development [Member] | EGEN, Inc. [Member]
Note 5 - Acquisition of EGEN, Inc. (Details) [Line Items]
Finite-lived Intangible Assets Acquired						25,800,000
Hercules Credit Agreement [Member] | EGEN, Inc. [Member]
Note 5 - Acquisition of EGEN, Inc. (Details) [Line Items]
Payments to Acquire Businesses, Gross							3,000,000
Loans Payable										5,000,000
EGEN, Inc. [Member] | Maximum [Member]
Note 5 - Acquisition of EGEN, Inc. (Details) [Line Items]
Business Combination, Consideration Transferred								44,400,000
EGEN, Inc. [Member]
Note 5 - Acquisition of EGEN, Inc. (Details) [Line Items]
Business Combination, Consideration Transferred	27,578,000							27,600,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	30,400,000					30,400,000			30,400,000
Payments to Acquire Businesses, Gross								3,000,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in Shares)	670,070							2,712,188
Business Combination, Consideration Transferred, Liabilities Incurred	13,878,000	[1]						13,900,000	13,700,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	13,700,000
Fair Value, Option, Changes in Fair Value, Gain (Loss)	231,949
Goodwill, Acquired During Period								2,000,000
Reporting Unit, Amount of Fair Value in Excess of Carrying Amount								2,000,000
Business Combination, Acquisition Related Costs						1,385,263
Operating Expenses						$ 2,297,000

[1] The total aggregate purchase price for the Egen Acquisition included potential future Earn-Out Payments contingent upon achievement of certain milestones. The difference between the aggregate $30.4 million in future Earn-Out Payments and the $13.9 million included in the fair value of the acquisition consideration at June 20, 2014 was based on the Company's risk-adjusted assessment of each milestone and utilizing a discount rate based on the estimated time to achieve the milestone. These milestone payments will be fair valued at the end of each quarter and any change in their value will be recognized in the financial statement. As of December 31, 2014, the Company fair valued these milestones at $13.7 million and recognized a gain of $231,949 as a result of the change in the fair value of these milestones from June 30, 2014.